

**THE EIGHTH ANNUAL MEETING**

**2002**

**JAPAN SOCIETY OF  
GENE THERAPY**

**PROGRAM AND ABSTRACTS**

**Date**

July 18-20, 2002

**Venue**

Hitotsubashi Memorial Hall

2-1-2, Hitotsubashi, Chiyoda-ku  
Tokyo

# GENERAL INFORMATION

**Registration fees:** ¥10,000

(¥5,000 Graduate Students and Postdoctoral Fellows)

**Registration Desk:**

Nametags and final programs will be distributed at the registration desk located on the second level of Hitotsubashi Memorial Hall. The registration desk will be open during the following hours:

*Thursday, July 18*                      *10:00 am - 5:00 pm*

*Friday, July 19*                        *9:00 am - 5:00 pm*

*Saturday, July 20*                      *9:00 am - 3:00 pm*

### *Instructions for Presenters in Oral Presentation Sessions*

All oral presentations at the annual meeting will be Power Point or 35 mm slide presentations. Please report to the Speaker Preview Section at least 1 hour before your presentation is scheduled.

**Session Formats:**

The formats of oral presentation sessions are as follows: The speakers for the oral sessions and the corporate symposium have been allotted 10 minutes to present their talks and 5 minutes to answer questions. The invited speakers for the international symposium and the presidential lectures have been asked to make 40 minutes presentations, and for the presidential symposium 20 minutes presentations on a topic relevant to the entire session, respectively.

**Note:**

Oral presenters are requested to make a presentation in English. No simultaneous interpretation will be provided.

### *Instructions for presenters in Poster Sessions*

Authors are requested to post and remove posters at designated times. All presenters should be in the poster area at least 15 minutes before the scheduled time to set up materials on the poster board provided.

**July 19:**

11:00-noon            *Poster Setup by Authors*

noon-18:20           *Poster viewing (Authors present from 17:40-18:20, odd numbers)*

**July 20:**

9:30-17:40           *Poster viewing (Authors present from 17:00-17:40, even numbers)*

17:40                 *Poster Take off by Authors*

**Poster Boards:**

The poster board assigned to each presenter has a usable area of 90 cm in width and 180 cm in height. The top left sections of 20 cm square will be used for an abstract number plate.

**Receptions:**

Within the highly demanding schedule, you will find that receptions are held Thursday evening at Josui kaikan, and Friday evening at a Japanese houseboat. Please contact our staff for an application at a registration desk. We hope you will be able to join us.

**Casual dress** is recommended for all participants including speakers and exhibitors. Although we realize some may feel more comfortable in a coat and tie, we believe a more casually dressed and comfortable group participates more freely and gains more from the meeting.

Please relax and enjoy your stay, but plan to actively participate. The staff is headquartered at the registration desk, and will gladly help you with any question or problem you may have during the meeting.

**For more information:**

For the latest information on all of the meeting, please visit the website at

**<http://bizweb.justnet.ne.jp/~jsgt/>**

Smoking is NOT allowed in a building except where posted "SMOKING AREA".

No food or drink in the boardrooms.

# PROGRAM OF 8TH JSJT ANNUAL MEETING

( ):Chairperson

July 18, Thursday		July 19, Friday	
9:10-9:55	*MANAGERS' MEETING	9:30-11:00	<b>Oral Session 2</b> <b>Gene Therapy</b> <b>of Congenital Disorders</b> (T. Okuyama, T. Ohashi) Abstracts14-19
9:55-10:40	*DIRECTORS' MEETING	11:10-12:10	<b>Cell &amp; Gene Targeting</b> (I. Saito, H. Kato) Abstracts20-23
10:40-11:25	*COUNCILORS' MEETING	13:30-14:10	<b>Presidential Lecture (1)</b> <i>Olivier Danos</i> (Y. Eto)
12:00-13:00	<b>Opening Remarks</b> <b>&amp; General Assembly</b> <i>Masami Muramatsu</i>	14:10-14:50	<b>Presidential Address</b> <i>Masami Muramatsu</i> (S. Asano)
13:10-15:10	<b>Oral Session 1</b> <b>Cancer Gene Therapy (1)</b> (N. Tanaka, H. Nakauchi) Abstracts1-8	15:00-16:00	<b>Cancer Gene Therapy (2)</b> (H. Hamada, T. Nukiwa) Abstracts24-27
15:20-16:20	<b>International Symposium</b> <b>(Gene Therapy in Asia)</b> <i>Suthat Fucharoen</i> (T. Ohno) <i>Sunyoung Kim</i> (F. Endo) <i>Xuetao Cao</i> (J. Yodoi) <i>Ning-Sun Yang</i> (M. Itakura)	16:25-17:40	<b>Vector Development (2)</b> (K. Tani, M. Hasegawa) Abstracts28-32
16:30-17:45	<b>Vector Development (1)</b> (K. Ozawa, K. Mitani) Abstracts9-13	17:40-18:20	<b>Poster Session 1</b> (Odd Numbers)
18:00	<b>Reception</b> at Josui Kaikan	19:00-21:30	<b>AsSGT</b> at a Japanese Houseboat

( ):Chairpersons

**July 20, Saturday**

9:30-11:00	<p><b>Oral Session 3</b> <b>Corporate Symposium</b> <b><i>Clinical Trials of Gene Therapy</i></b> <i>Leonard E. Post</i> (Y. Kaneda) <i>Shu Fen Wen</i> (J. Yoshida) <i>DC Yu</i> (T. Yoshida) <i>Daniel R. Marshak</i> (N. Emi) <i>Gabor Veres</i> (H. Tahara) <i>Markus Müller</i> (S. Tsuji)</p>
11:20-12:00	<p><b>Presidential Lecture (2)</b> <i>Malcolm K. Brenner</i> (N. Saijo)</p>
13:30-14:10	<p><b>Presidential Lecture (3)</b> <i>Ian Alexander</i> (T. Shimada)</p>
14:20-15:20	<p><b>Presidential Symposium</b> <b><i>Cell Specific Gene Expression</i></b> <b><i>towards Gene Therapy</i></b> <i>Hiroyuki Mizuguchi</i> <i>Izumu Saito</i> <i>Masayuki Yamamoto</i> (H. Hirai, Y. Matsubara)</p>
15:30-17:00	<p><b>Gene Therapy</b> <b>of Acquired Disorders</b> (K. Okuda, J. Fujimoto) Abstracts33-38</p>
17:00-17:40	<p><b>Poster Session 2</b> (Even Numbers)</p>
17:40	<p><b>Closing Remarks</b> <i>Masami Muramatsu</i></p>

***Presidential Address***

***Date: July 19, 2002***

***Time: 14:10-14:50***

***Masami Muramatsu*** (Chairperson: Shigetaka Asano)

From Genome to Gene Therapy

***International Symposium: Gene Therapy in Asia***

***Date: July 18, 2002***

***Time: 15:20-16:20***

***Suthat Fucharoen*** (Chairperson: Tsuneya Ohno)

Corretion of Hb E Mutation with Aberrant Splicing in the Exon Generating Correct mRNA and Protein Production

***Sunyong Kim*** (Chairperson: Fumio Endo)

Development of Effective Gene Delivery Technologies to Human CD34<sup>+</sup> Stem Cells and Their Applications to Human Diseases

***Xuetao Cao*** (Chairperson: Noriyuki Kasahara)

Attracting T Cells and Dendritic Cells for Efficient Antigen Presentation and T Cell Activation: A Powerful Approach to Cancer Gene Therapy

***Ning-Sun Yang*** (Chairperson: Mitsuo Itakura)

Gene Gun and Micro-Seeding Technologies for Developing DNA Vaccine Strategies against Cancerous or Infections Diseases

***Presidential Lecture (1)***

***Date: July19, 2002***

***Time: 13:30-14:10***

***Olivier Danos*** (Chairperson: Yoshikatsu Eto)

Gene and Cell-Based Approaches for Engineering and Repairing the Skeletal Muscle

***Presidential Lecture (2)***

***Date: July20, 2002***

***Time: 11:20-12:00***

***Malcolm K Brenner*** (Chairperson: Nagahiro Saijo)

Progress and Problems in Clinical Gene Therapy

***Presidential Lecture (3)***

***Date: July20, 2002***

***Time: 13:30-14:10***

***Ian Alexander*** (Chairperson: Takashi Shimada)

Treatment of an Infant with NK<sup>+</sup> Severe Combined Immunodeficiency(SCID)-X1 by Gene Therapy in Australia

***Presidential Symposium:***

***Cell Specific Gene Expression towards Gene Therapy***

***Date: July 20, 2002***

***Time: 14:20-15:20***

(Chairpersons: Hisamaru Hirai, Youichi Matsubara)

***Hiroyuki Mizuguchi***

Single Adenovirus Vector Containing Both rtTA and tTS Expression Cassettes Provides Tight Regulation of Transgene Expression in a Positive Manner

***Izumu Saito***

Cancer-Specific Gene Expression Based on Gene Regulation Using Site-Specific Recombinases

***Masayuki Yamamoto***

Molecular Dissection of GATA-1 Gene Hematopoietic Regulatory Domain

***Corporate Symposium: Clinical Trials of Gene Therapy***

***Date: July 20, 2002***

***Time: 9:30-11:00***

***Leonard E. Post*** (Chairperson: Yasufumi Kaneda)

Selectively Replicating Adenoviruses as Therapeutic Agents and Vectors for Specific Expression of Genes in Cancer Cells

***Shu Fen Wen*** (Chairperson: Jun Yoshida)

Adenovirus-Based Tumor Suppressor Gene Therapy for Cancer: Clinical Experience with rAd-p53

***DC Yu*** (Chairperson: Teruhiko Yoshida)

Selectively Replicating Viruses as Oncolytic Agents against Cancer

***Daniel R. Marshak*** (Chairperson: Nobuhiko Emi)

Mesenchymal Stem Cells

***Gabor Veres*** (Chairperson: Hideaki Tahara)

Development of HIV-1 Based Vectors for Clinical Applications

***Markus Müller*** (Chairperson: Syouji Tsuji)

Large-Scale Manufacture of Plasmid DNA for Pharmaceutical Applications: Current Plasmid Quality Standards-Contamination-Process Challenges and Solutions

**PROGRAM**  
**Oral Session 1 (Abstracts 1-13)**

**Day 1: July 18, 2002**

*Cancer Gene Therapy (1) 13:10-15:10*

**Chairpersons: Noriaki Tanaka, Hiromitsu Nakauchi**

1. **Evidence for the Expansion of the MDR1-Transduced Cells *In Vivo* in a Clinical Study of MDR1 Gene Therapy Against Breast Cancer**  
*Sugimoto Y., Takahashi S., Nakane M., Mitsunashi J., Tsukahara S., Nagamine T., Minowa S., Shibata H., Ito Y., Hatake K., Tsuruo T., Horikoshi N., Aiba K.*
  
2. **Adenovirus Vectors for Tumour and Stem Cell Gene Therapy**  
*Lieber A.*
  
3. **Interim Report of Safety, Efficacy, Transgene Expression, and Shedding in Biological Fluids Following Intratumoral Administration of Adenovirus Expressing Wild-Type p53 Gene (Ad-p53) in Advanced Lung Cancer Patients**  
*Fujiwara T., Kataoka M., Kagawa S., Nakamura A., Tanaka N.*
  
4. **Transfusion of Donor Lymphocytes Transduced with the Herpes Simplex Thymidine Kinase Gene into Patients with Relapsed Leukemia After Allogeneic Bone Marrow Transplantation**  
*Onodera M., Kaneko S., Kojima H., Hasagawa Y., Fukushima T., Sumazaki R., Matsui A., Nagasawa T., Nakauchi H.*
  
5. **Suppression of Tumor Growth by Lentiviral Mediated Systemic Antiangiogenic Gene Therapy in Non-Hodgkin Lymphoma**  
*Miyake K., Suzuki N., Shimada T.*
  
6. **Human  $\beta$ -Interferon Gene Therapy for Malignant Glioma Clinical Trials**  
*Yoshida J., Mizuno M., Kajita Y., Fujii M., Wakabayashi T.*

7. **Phase I/II Study of Adenoviral Vector Delivery of HSK-TK Gene and the Intravenous Administration of Ganciclovir in Men with Local Recurrence of Prostate Cancer after Hormonal Therapy**

*Nasu Y., Ebara S., Saika T., Tsushima T., Thompson TC., Kumon H.*

8. **Preclinical Studies of Autologous Immuno-Gene Therapy for Neuroblastoma**

*Manabe A., Hirose I., Tsuji K., Yamashita N.*

### ***Vector Development (1) 16:30-17:45***

**Chairpersons: Keiya Ozawa, Kounosuke Mitani**

9. **Second Generation Selective Amplifier Genes for Efficient *In Vivo* Expansion of Gene Modified Hematopoietic Cells**

*Nagashima T., Ueda Y., Hanazono Y., Kume A., Shibata H., Ageyama N., Komatsu N., Terao K., Ozawa K., Hasegawa M.*

10. **Helper-Independent Chromosomal Integration of Naked Double-Stranded Linear DNA Vectors in Mice**

*Nakai H., Montini N., Fuess S., Storm TA., Meuse L., Finegold M., Grompe M., Kay MA.*

11. **Host Chromosomal Effects of Naked Plasmid DNA Vector Integration in Mice**

*Nakai H., Montini N., Fuess S., Storm TA., Meuse L., Finegold M., Grompe M., Kay MA.*

12. **Production of Recombinant Adeno-Associated Virus Type 2 in Insect Cells**

*Urabe M., Ding C., Kotin RM.*

13. **Development of an Adenoviral/Lentiviral Hybrid Vector for Efficient and Long-Term Gene Expression**

*Kubo S., Mitani K.*

## Oral Session 2 (Abstracts 14-32)

Day 2: July 19, 2002

*Gene Therapy of Congenital Disorders 9:30-11:00*

Chairpersons: Takashi Shimada, Toya Ohashi

14. **Functional Analysis of an Insulator Vector for Human Gamma-Globin in Mouse Model for  $\beta$  Thalassemia**  
*Nishino T., Yannaki E., Stamatoyannopoulos G., Emery DW.*
15. **Inhibition of Neovascularization in a Murine Proliferative Retinopathy Model by Lentivirus Mediated Expression of Angiostatin**  
*Igarashi T., Miyake K., Kato M., Kato K., Suzuki N., Ishizaki M., Takahashi H., Ohara K., Shimada T.*
16. **Complete Normalization of Skeletal Problems in Mice with Mucopolysaccharidosis Type VII by Neonatal Gene Therapy Mediated by Adenoviral Vectors**  
*Kanaji A., Kosuga M., Tanabe A., Kamata Y., Azuma N., Yamada M., Sakamaki T., Toyama Y., Okuyama T.*
17. **Transfer of Maternally Administrated Liposome-DNA Complex into Fetus in a Pregnant Primate Model**  
*Nakamura S., Hirano M., Mitsunaga F., Shimuzu K., Okada M., Imamura T.*
18. **Development of AAV Vector Mediated Enzyme Replacement Therapy for Fabry Disease: Echocardiographic Evaluation of Gene Therapy of Fabry Mice**  
*Takahashi H., Hirai Y., Seino Y., Hashimoto Y., Sakuraba H., Shimada T.*
19. **Long-Term Correction of Central Diabetes Insipidus by Stereotaxic Injection of AAV Vector-Expressing Arginine-Vasopressin into Hypothalamus in Brattleboro Rats**  
*Ideno J., Mizukami H., Honda K., Okda T., Hanazono Y., Kume A., Saito T., Ishibashi S., Ozawa K.*

***Cell and Gene Targeting 11:10-12:10***

**Chairpersons: Izumu Saito, Harubumi Kato**

20. **Bone Regeneration Using Mesenchymal Stem Cells Transduced by Adenoviral Vectors with RGD-Modified Fiber**

*Tsuda H., Wada T., Ito Y., Sasaki K., Kobune M., Uchida H., Dehari H., Nakamura K., Ishii S., Hamada H.*

21. **Clonal Insertion Analysis of Gene-Modified Hematopoietic Cells After Hematopoietic Reconstitution with Retrovirally-Transduced CD34<sup>+</sup> Cells in Nonhuman Primates.**

*Takatoku M., Hanazono Y., Nagashima T., Shibata H., Ageyama N., Ueda Y., Kume A., Dunbar CE., Terao K., Hasegawa M., Ozawa K.*

22. **Death of Ph1-Positive Acute Lymphoblastic Leukemia Cells with Transduction of Maxizyme Targeting Minor Bcr-Abl Fusion Gene Using a Third-Generation Lentiviral Vector System**

*Soda Y., Tani K., Bai Y., Takata I., Kuwabara T., Warashina M., Tanabe T., Saiki M., Chen M., Li X., Miyoshi H., Sugita K., Nakazawa S., Tojo A., Taira K., Asano S.*

23. **Gene Therapy for Non-Small Cell Lung Cancer Using p53 Adenovirus Vector Combined with Cisplatin**

*Nakamura H., Saji H., Kawasaki N., Ogata A., Hosaka M., Kato H.*

***Cancer Gene Therapy (2) 15:00-16:15***

**Chairpersons: Hirofumi Hamada, Toshihiro Nukiwa**

24. **Enhanced and Selective Transduction by M Gene-Deficient Sendai Virus Vectors Inhibits Protease-Rich Metastatic Tumor Growth**

*Kinoh H., Inoue M., Washizawa K., Yamamoto T., Iida A., Hasegawa M.*

25. **In Situ Generation of Pseudotyped Retroviral Progeny by Adenovirus-Mediated Transduction of Glioma Cells Enhances Killing Effect of HSV-TK Suicide Gene *In Vitro* and *In Vivo***

*Okada T., Ajalli R., Onodera M., Ramsey WJ., Mizukami H., Hanazono Y., Kume A., Hamada H., Blaese RM., Ozawa K.*

26. **Combination Gene Therapy of SLPI Promoter Controlled Replication Competent Adenovirus and NK4 Encoding Adenovirus Vector for Non-Small Cell Lung Cancer**

*Maemondo M., Narumi K., Saijo Y., Kikuchi T., Tazawa R., Hagiwara K., Takahashi M., Niitsu Y., Nukiwa T.*

27. **Systemic Cytokine Gene Therapy Suppresses Metastatic Sarcoma and Cancer in Mice**

*Itokawa Y., Ueda Y., Kishida T., Asada H., Cui FD., Fuji N., Fujiwara H., Imanishi J., Yamagishi H., Mazda O.*

***Vector Development (2) 16:25-17:40***

**Chairpersons: Kenzaburo Tani, Mamoru Hasegawa**

28. **Targeted Gene Correction Using Helper-Dependent Adenoviral Vectors**

*Balamotis MA., Mitani K.*

29. **Efficient Gene Transfer into Human CD34<sup>+</sup> Cells by an Adenovirus Type 35 Vector**

*Sakurai F., Mizuguchi H., Hayakawa T.*

30. **Sendai Virus Vectors with Improved Tropism and Safety: Modification of Hemagglutinin-Neuraminidase (HN) Protein with a Folate-Conjugated Monoclonal Antibody**

*Hara H., Sakakibara H., Ueda Y., Hasegawa M.*

31. **A Novel Packaging System of HIV Vectors Using CHO Based Stable Packaging Cell Line and an Adenovirus Based Expression Vectors**

*Miyake K., Suzuki N., Shimada T.*

32. **Influence of Gene Transduction with a Third-Generation Selfinactivating Lentiviral Vector to the Gene Expression of Human CD34-Positive Hematopoietic Cells**

*Bai Y., Soda Y., Tani K., Saiki M., Nakazaki Y., Li X., Chen M., Izawa K., Sasaki E., Nishioka C., Oiwa M., Takahashi K., Tojo A., Miyoshi H., Katagiri T., Takahashi T., Nakamura Y., Asano S.*

## Oral Session 3 (Abstracts 33-38)

Day 3: July 20, 2002

*Gene Therapy of Acquired Disorders 15:30-17:00*

Chairpersons: Kenji Okuda, Jiro Fujimoto

33. **Oral Administration of Recombinant Adeno-Associated Virus Elicits Protective Immunity against HIV-1**

*Xin KQ., Mizukami H., Ozawa K., Okuda K.*

34. **A Preclinical Safety Study for Intramuscular Administration of F-Defective, Non-Transmissible Recombinant Sendai Virus Vector Using Non-Human Primate**

*Yonemitsu Y., Terao K., Ono F., Kuwahara T., Iida A., Hara H., Iwasaki H., Hasegawa M., Sueishi K.*

35. **Anti-MCP-1 Gene Therapy Against Restenosis and Atherosclerosis**

*Egashira K.*

36. **Recombinant Sendai Virus-Mediated Intramuscular Gene Transfer of FGF-2 Restores Collateral Blood Perfusion of Chronically Ischemic Rabbit Hind Limb, and Inhibits Neointimal Hyperplasia of Autologous Femoral Vein Grafts**

*Yonemitsu Y., Komori K., Shoji T., Sugimachi K., Hasegawa M., Sueishi K.*

37. **Intramuscular Delivery of AAV-GDNF Delayed the Disease Progression in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis**

*Wang LJ., Lu YY., Muramatsu S., Ikeguchi K., Fujimoto K., Okada T., Mizukami H., Matsushita T., Hanazono Y., Kume A., Nagatsu T., Ozawa K., Nakano I.*

38. **NF- $\kappa$ B Decoy Oligodeoxynucleotides(ODN) Inhibits CCL4-Induced Liver Injury And Fibrosis In Mice**

*Son G., Ogusi I., Hirano T., Iimuro Y., Fujimoto J.*

## Poster Session

Day 2: July 19, 2002 (17:40-18:20, Odd Numbers)

Day 3: July 20, 2002 (17:00-17:40, Even Numbers)

### *Cancer Gene Therapy*

39. **Cell Growth-Linked Midkine Promoter Can Activate Foreign Gene in Human Breast Cancer and Hepatocellular Carcinoma**  
*Yu L., Tomizawa M., Kadomatsu K., Muramatsu T., Matsubara S., Sakiyama S., Tagawa M.*
40. **Therapeutic Efficacy of Combined Replicative Adenovirus and Non-Replicative Adenovirus Expressing IL-12 Studied in an Immunocompetent Mouse Model**  
*Nagayama Y., Nakao K., Mizuguchi H., Hayakawa T.*
41. **Experimental Gene Therapy for Gallbladder Cancer Using Tumor-Specific Replicating E1 Mutant Adenoviral Vectors**  
*Fukuda K., Abei M., Ugai H., Seo E., Hamada H., Tanaka N., Yokoyama K.*
42. **Combination of 5-Fluorocytosine/Cytosine Deaminase Suicide Gene Therapy with Replication Competent Adenovirus for Human Glioma Cell Lines**  
*Ohtsuka S., Kurozumi K., Kambara H., Ono Y., Tamiya T., Hamada H., Ohmoto T.*
43. ***In Vivo* Transduction with Interleukin (IL) -21 and IL-15 Genes Resulted in Complete Regression of Lymphoma Metastasis in Murine Liver**  
*Kishida T., Asada H., Cui FD., Imanishi J., Mazda O.*
44. **Adenovirus Mediated ICAM-2 Transfection to Cancer Cells Is a Useful Immuno-Gene Therapy for the Peritoneal Metastasis of Scirrhous Gastric Carcinoma**  
*Kosaka K., Yashiro M., Tanaka H., Hirakawa K.*
45. **Enhancement of Antitumor Effect on Drug-Sensitivity by Treatment with Antisense HER-2 in Gastric Carcinoma Cells**  
*Kim R., Tanabe K., Toge T.*

46. **Immunological Mechanisms of Anti-Tumor Effects Generated by Interferon- $\beta$  Gene Therapy in the Treatment of Intraperitoneal Malignancy**  
*Odaka M., Tanaka T., Albelda SM., Yamazaki Y.*
47. **Apoptosis Induction with 5-Fluorocytosine/Cytosine Deaminase (5-FC/CD) Gene Therapy Mediated by Adenovirus for Human Malignant Glioma Cells**  
*Kurozumi K., Tamiya T., Otsuka S., Kambara H., Adachi Y., Ichikawa T., Ono Y., Ohmoto T., Hamada H.*
48. **Proliferative Effect of Hepatocyte Growth Factor (HGF) and Relevance of the HGF/C-Met Signal Transduction Pathways in Rat Oval Cells**  
*Okano J., Shiota G., Murawaki Y.*
49. **Efficient Introduction of EGFP RNA in Human Hematopoietic Cells by Electroporation**  
*Takahashi M., Narita M., Flavio A., Liu A., Furukawa T., Toba K., Aizawa Y.*
50. **Therapeutic Effect of Intravenous Interferon Gene Delivery with Naked DNA in Murine Metastasis Models**  
*Watanabe Y., Kobayashi N., Kuramoto T., Chen S., Takakura Y.*
51. **Enhancement of Thymidine Kinase-Mediated Killing of Malignant Glioma by Bims, a BH3-only Cell Death Activator**  
*Yamaguchi T., Okada T., Nagai M., Takeuchi K., Shinoda S., Masuzawa T., Ozawa K., Inaba T.*
52. **The Effect of HGF on the Growth of Hepatocellular Carcinoma *In Vivo***  
*Morikawa S., Hirano T., Ueki T., Imuro Y., Fujimoto J.*
53. ***In Vitro* Thymidine Kinase/Ganciclovir-Based Suicide Gene Therapy Against Malignant Lymphoproliferative Disorders Mediated by Replication Defective Herpes Simplex Virus-1**  
*Kuwayama Y., Misumi M., Suzuki T., Yoshida K., Bessho M., Moriuchi S., Glorioso JC., Muramatsu M.*
54. **Gene Therapy for Hodgkin's Lymphoma by Means of Replication Defective Herpes Simplex Virus-1 Overexpressing Mutant I $\kappa$ B $\alpha$**   
*Misumi M., Kuwayama Y., Suzuki T., Yoshida K., Moriuchi S., Muramatsu M., Bessho M.*

55. **Enhanced Anti-CD20 Monoclonal Antibody-Based Immunotherapy Against Lymphoma Mediated by HSV-1 Suicide Gene Therapy *In Vitro***  
*Suzuki T., Misumi M., Kuwayama Y., Yoshida K., Bessho M., Moriuchi S., Glorioso JC., Muramatsu M.*
56. **Induction of Antitumor Immunity Using Dendritic Cells Genetically Engineered to Express Tumor Antigen Is Enhanced by the Co-Transduction of GM-CSF Gene**  
*Ojima T., Iwahashi M., Nakamura M., Nakamori M., Ueda K., Matuura I., Yamaue H.*
57. **Suppression of Liver Metastases by Intramuscular Administration of Recombinant Adeno-Associated Virus Vector Expressing Endostatin in Golden Hamster Model of Pancreatic Cancer**  
*Noro T., Miyake K., Suzuki N., Uchida E., Yamazaki Y., Shimada T.*
58. **Intracerebral Grafting of Hematopoietic Stem Cells Genetically Modified by the VSV-G Pseudo-Type Retroviral Vector Gcdnsap as a New Gene and Cellular Therapy for Neurological Disorders**  
*Shimizu T., Onodera M., Kaneko S., Mochizuki H., Nagasawa T., Nakauchi H.*
59. **Epstein-Barr Virus Replicon Vector System Enhances the Transgene Expression: Applications to Gene Therapy for Melanoma**  
*Yamamoto S., Otomo T., Saeki Y., Morishita R., Kaneda Y.*
60. **Expression of the Interleukin-21 Gene in Murine Colon Carcinoma Cells Produced T Cell and Natural Killer Cell Dependent Antitumor Effects**  
*Ugai S., Wang Y., Shimozato O., Yamaguchi T., Kawamura K., Saisho H., Sakiyama S., Tagawa M.*
61. **Stimulation of Adenoviral Wild-Type p53 Induced Apoptotic Cell Death by Overexpression of P33ING1 in T.Tn Human Esophageal Carcinoma Cells**  
*Shimada H., Ochiai T., Hiwasa T.*
62. **Anti-Tumor Activity of IAB-1 (Cationic MLV Liposomes Containing Human Interferon- $\beta$  Gene) Against Human Renal Cell Carcinoma**  
*Nakanishi H., Mizutani Y., Mizuno M., Nakao M., Mazda O., Imanishi J., Yoshida J., Miki T.*

63. **Augmented Tumor-Specific p53 Gene Therapy for Hepatocellular Carcinoma in Combination with Selectively Replication Competent Adenovirus and Chemotherapeutic Agent**

*Yamada Y., Takahashi M., Sato Y., Fukaura J., Sato T., Iyama S., Oku T., Sumiyoshi T., Sagawa T., Niitsu Y.*

64. **Gene Therapy for Bladder Cancer by Dual-Restricted Replication-Competent Adenovirus with RGD-Modified Fiber**

*Dehari H., Ito Y., Sasaki K., Kobune M., Uchida H., Nakamura T., Hamada H.*

65. **Immunohistochemical Determination of Anti-Renal Cell Carcinoma Immunity Elicited by GM-CSF Gene Transduced Lethally Irradiated Autologous Tumor Cell Vaccine (GVAX)**

*Oyaizu N., Tani K., Nakazaki Y., Hase H., Takahashi K., Monma M., Ohata J., Watari K., Satoh N., Tojo A., Yamashita N., Maekawa T., Eriguchi M., Tomikawa S., Hanazawa K., Wakumoto Y., Kawai K., Azuma M., Kakizoe T., Okumura K., Akaza H., Fujime M., Mulligan R., Clift S., Ando D., Sherwin S., Asano S.*

66. (This poster has been moved to “Gene Therapy of Acquired Disorders” section.)

### ***Gene Therapy of Congenital Disorders***

67. **Correction of Hyperphenylalanemia and Hypopigmentation in Phenylketonuria Mice by Adeno-Associated Virus-Mediated Gene Transfer into the Liver**

*Mochizuki S., Mizukami H., Okada T., Hanazono Y., Kobayashi E., Matsubara Y., Hoshika A., Ozawa K., Kume A.*

68. **Idennet, an Internet Resource for Clinical Genetics and Survey on Today's Clinical Gene Therapy Research & Development in Japan**

*Fujita J., Itoh K.*

69. **Micro-Dystrophin cDNA Ameliorates Dystrophic Phenotypes When Introduced into *mdx* Mice as a Transgene**

*Sakamoto M., Yuasa K., Yoshimura M., Yokota T., Masuda S., Ikemoto T., Miyagoe-Suzuki Y., Takeda S.*

70. **Gene Transfer to CNS by Intrauterine Administration of Adenovirus**

*Shen JS., Meng XL., Ohashi T., Eto Y.*

71. **Utrophin mRNA Stability Can Be Involved in Utrophin Over-Expression in AxCALacZ-Injected Neonatal *mdx* Skeletal Muscles**

*Itoh Y., Fujimori K., Miyagoe-Suzuki Y., Takeda S.*

72. **Gene Therapy for the Brain of GM1 Gangliosidosis Murine Model by Intravenous Administration of  $\beta$ -Galactosidase Gene in Adenovirus Vector**

*Takaura N., Yagi T., Maeda M., Ogawa Y., Nanba E., Ohshima A., Matsuda J., Suzuki Y., Yamano T., Tanaka A.*

### *Gene Therapy of Acquired Disorders*

66. **Adeno-Associated Viral Vector Gene Transfer to the Brain for Novel Models of Neurodegenerative Diseases**

*Klein RL., Gong Y., Meyer EM., King MA.*

73. **Gene Therapy for Rat Liver Cirrhosis by Hepatocyte Growth Factor (HGF) Naked Plasmid DNA Transfer into Liver**

*Kanemura H., Takeuchi M., Iimuro Y., Ueki T., Hirano T., Horiguchi K., Asano Y., Fujimoto J.*

74. **HGF Gene Therapy of Dog Liver Cirrhosis Via Hepatic Artery**

*Horiguchi K., Takeuchi M., Ueki T., Hirano T., Kanemura H., Asano Y., Iimuro Y., Fujimoto J.*

75. **Sendai Virus Vectors Carrying Neurotrophic Factor Genes Rescue Model Animals from Ischemic Brain Injury by Several Hours Post-Ischemic Administration**

*Shirakura M., Inoue M., Fukumura M., Fujikawa S., Komaba S., Washizawa K., Yamamoto T., Maeda M., Watabe K., Yoshikawa Y., Hasegawa M.*

76. **Treatment of Murine Lupus Nephritis by Chemokine Antagonists**

*Hasegawa H., Kohno M., Sasaki M., Inoue A., Nose M., Fujita S.*

77. **Intravenous Injection of Naked Plasmid Encoding Hepatocyte Growth Factor Ameliorates Bleomycin-Induced Pulmonary Fibrosis**

*Watanabe M., Ebina M., Miki M., Tahara M., Hagiwara K., Nakamura T., Nukiwa T.*

78. **Intramuscular Injection of AAV Vector-Expressing IL-10 for Prevention of Atherosclerosis**  
*Yoshioka T., Okada T., Maeda Y., Shimpo M., Nomoto T., Takeuchi K., Mizukami H., Hanazono Y., Kume A., Ohgawara S., Ikeda U., Shimada K., Ozawa K.*
79. **Hepatic Insulin Gene Therapy of STZ-Diabetic Mouse by Intravenous Administration of Naked Epstein-Barr Virus (EBV) -Based Plasmid Vectors**  
*Yasutomi K., Kishida T., Imanishi J., Takeuchi T., Mazda O.*
80. **Brain Malformation Caused by a Unique Gene Transfer to the CNS Through Embryonic Mouse Ventricles**  
*Matsukawa N., Ikenaka K., Yuasa H., Hattori M., Otsuka Y., Fujimori O., Ueda R., Ojika K.*

### *Cell and Gene Targeting*

81. **CXCR4-Targeting, Ecotropic Murine Leukemia Virus-Based Retroviral Vector**  
*Katane M., Takao E., Kubo Y., Fujita R., Amanuma H.*
82. **Soluble Car-Scf Fusion Proteins Improve Adenoviral Vector Mediated Gene Transfer to Human Hematopoietic Cells**  
*Itoh A., Okada T., Mizuguchi H., Hayakawa T., Mizukami H., Kume A., Hanazono Y., Ozawa K.*
83. **Cell-Specific Gene Transfer by  $\alpha$ -Cyclodextrin Conjugates with Mannosylated Polyamidoamine Dendrimers**  
*Arima H., Wada K., Kihara F., Hirayama F., Uekama K.*
84. **In Situ HSVtk Gene Transfer to Chemically-Induced Rat Urinary Bladder Carcinomas Using *In Vivo* Electroporation**  
*Shibata M., Horiguchi T., Morimoto J., Otsuki Y.*
85. **Development of Gene Therapy Targeting Neutrophil Disorders Using Gene-Modified Neutrophils**  
*Li X., Tani K., Soda Y., Bai Y., Saiki M., Sasaki E., Izawa K., Nakazaki Y., Miyoshi H., Tojo A., Asano S.*

86. **Hvj-Liposome Mediated Gene Delivery into Mouse Inner Ear**  
*Doi K., Oshima K., Kubo T., Kaneda Y.*
87. **Molecular Mechanism of Oligonucleotide-Mediated Gene Repair**  
*Ikejima M., Shimada T.*
88. **Local Gene Delivery System into the Kidney Using Low Voltage Ultrasound and Microbubble**  
*Tomita N., Morishita R., Koike H., Taniyama Y., Azuma H., Higaki J., Ogihara T.*
89. **Rested Cell Reinfusion Improves Engraftment of Retrovirally Transduced Hematopoietic Cells in Nonhuman Primates**  
*Takatoku M., Sellers S., Agricola BA., Metzger ME., Kato I., Donahue RE., Dunbar CE.*
90. **Human Mitochondrial Fusiogenic Protein Complex and Ooplasmic Transfer**  
*Fukushima-Hiraoka M., Sato A., Hamamoto T., Endo H., Kagawa Y.*
91. **Airway-Directed Gene Transfer of Interleukin-10 Using Recombinant Sendai Virus Effectively Prevents Post-Transplantation Bronchiolitis Obliterans in Mice**  
*Shoji F., Yonemitsu Y., Okano S., Yoshino I., Nakagawa K., Nakashima Y., Hasegawa M., Sugimachi K., Sueishi K.*

### ***Vector Development***

92. **Simian Immunodeficiency Virus-Based Lentivirus Vector for Retinal Gene Transfer: a Preclinical Safety Study in Adult Rats**  
*Ikeda Y., Yonemitsu Y., Miyazaki M., Goto Y., Sakamoto T., Ishibashi T., Tabata T., Ueda Y., Hasegawa M., Tobimatsu S., Sueishi K.*
93. **Regression of Ocular Neovascularization by Increased Expression of Pigment Epithelium-Derived Factor**  
*Mori K., Gehlbach P., Ando A., Mcvey D., Wei L., Campochiaro PA.*

94. **Atelocollagen-Based Gene Transfer in Cells Allows High-Throughput Screening of Genes Functions**  
*Honma K., Ochiya T., Nagahara S., Sano A., Hirai K., Aso Y., Terada M.*
95. **Novel Types of Sendai Virus Vector Deficient in the Matrix Gene (Sev/ M) or Matrix/Fusion Genes (Sev/ M F) : Efficient Gene Transfer with Preferable and Unique Properties**  
*Inoue M., Tokusumi Y., Ban H., Kanaya T., Shirakura M., Nagai Y., Iida A., Hasegawa M.*
96. **Generation of Fiber-Modified Adenovirus Vector Containing Heterologous Peptides in Both the HI Loop and C Terminal of the Fiber Knob**  
*Koizumi N., Mizuguchi H., Utoguchi N., Watanabe Y., Hayakawa T.*
97. **Distinct Patterns of Gene Transfer to Gerbil Hippocampus with Recombinant Adeno-Associated Virus Type 2 and 5**  
*Nomoto T., Okada T., Shimazaki K., Mizukami H., Matsushita T., Hanazono Y., Kume A., Katsura K., Katayama Y., Ozawa K.*
98. **Maintenance of Retroviral Gene Expression Requires Brm, a Catalytic Subunit of Swi/Snf Complex**  
*Mizutani T., Ito T., Nishina M., Yamamichi N., Watanabe A., Iba H.*
99. **Recent Advance in Herpes Simplex Virus-Based Vector Systems**  
*Saeki Y., Terada K., Wakimoto H., Tyminski E., Martins RW., Chiocca EA.*
100. **High Concentrations of rAAV Administered to Liver Result in a Non-Linear Dose Response**  
*Nakai H., Thomas CE., Storm TA., Fuess S., Powell S., Wright F., Kay MA.*
101. **Virus Core-Bank Projects: Recombinant Adenoviral Vectors as a Tool for Functional Research**  
*Ugai H., Suzuki E., Kujime Y., Watanabe S., Hirose M., Murata T., Yokoyama K.*

102. **Optimizing Liver and Muscle-Directed Expression of Adeno Associated Virus (AAV) Vectors by Promoters and Serotypes**  
*Mochizuki S., Mizukami H., Kume A., Muramatsu S., Matsushita T., Okada T., Hanazono Y., Hoshika A., Kobayashi E., Ozawa K.*
103. **Modification of Recombinant Sendai Virus Vector with Polyethylene Glycol Altered the Stability in Blood and Protected the Vector from Neutralizing Antibody**  
*Sakakibara H., Hara H., Ueda Y., Hasegawa M.*
104. **Highly Efficient Gene Transfer to Solid Tumors *In Vivo* by Targeted Replication-Competent Retrovirus Vectors**  
*Logg C., Logg A., Tai CK., Wang W., Chen T., Bochner BH., Kasahara N.*
105. **Development of Self-Inactivating Lentiviral Vectors for Genetic Immunotherapy of Acute Myeloid Leukemia**  
*Kasahara N., Koya R., Pullarkat V., Levine AM., Stripecke R.*
106. **Efficient Infection of Cancer Cell Lines with an Adenoviral Vector with Different Serotype Tropism**  
*Huang K., Mitani K.*
107. **Large-Scale Manufacture of Plasmid DNA for Pharmaceutical Applications: Current Plasmid Quality Standards-Contamination-Process Challenges and Solutions**  
*Müller M.*
108. **Establishment of Operation Procedure to Detect Adenovirus E1A and E1B**  
*Murata T., Watanabe S., Kujime Y., Hirose M., Ugai H., Suzuki E., Yokoyama K.*
109. **Optimization of Upstream Parameters Influencing Plasmid DNA Quality and Yield in Large Scale Manufacturing Processes**  
*Breul A.*

**110. Construction of the Hematopoietic Lineage Specific Gene Expression System with an HIV-1 Derived Self-Inactivation Lentiviral Vector**

*Yasui K., Furuta RA., Matsumoto K., Tani Y., Fujisawa J.*

**111. Transferrin-Conjugated Liposome for IL-12 Gene Therapy**

*Joo SY, Kim JS.*

Abei M.	41	Cui FD.	27, 43	Fukushima T.	4
Adachi Y.	47	Dehari H.	20, 64	Fukushima-Hiraoka M.	90
Ageyama N.	9, 21	Ding C.	12	Furukawa T.	49
Agricola BA.	89	Doi K.	86	Furuta RA.	110
Aiba K.	1	Donahue RE.	89	Gehlbach P.	93
Aizawa Y.	49	Dunbar CE.	21, 89	Glorioso JC.	53, 55
Ajalli R.	25	Ebara S.	7	Gong Y.	66
Akaza H.	65	Ebina M.	77	Goto Y.	92
Albelda SM.	46	Egashira K.	35	Grompe M.	10, 11
Amanuma H.	81	Emery DW.	14	Hagiwara K.	26, 77
Ando A.	93	Endo H.	90	Hamada H.	20, 25, 41, 42, 47, 64
Ando D.	65	Eriguchi M	65	Hamamoto T.	90
Arima H.	83	Eto Y.	70	Hanazawa K.	65
Asada H.	27, 43	Finegold M.	10, 11	Hanazono Y.	9, 19, 21, 25
Asano S.	22, 32, 65, 85	Flavio A.	49		37, 67, 78, 82, 97, 102
Asano Y.	73, 74	Fuess S.	10, 11, 100	Hara H.	30, 34, 103
Aso Y.	94	Fuji N.	27	Hasagawa Y.	4
Azuma H.	88	Fujii M.	6	Hase H.	65
Azuma M.	65	Fujikawa S.	75	Hasegawa H.	76
Azuma N.	16	Fujime M	65	Hasegawa M.	9, 21, 24, 30
Bai Y.	22, 32, 85	Fujimori K.	71		34, 36, 75, 91, 92, 95, 103
Balamotis MA.	28	Fujimori O.	80	Hashimoto Y.	18
Ban H.	95	Fujimoto J.	38, 52, 73, 74	Hatake K.	1
Bessho M.	53, 54, 55	Fujimoto K.	37	Hattori M.	80
Blaese RM.	25	Fujisawa J.	110	Hayakawa T.	29, 40, 82, 96
Bochner BH.	104	Fujita J.	68	Higaki J.	88
Breul A.	109	Fujita R.	81	Hirai K.	94
Campochiaro PA.	93	Fujita S.	76	Hirai Y.	18
Chen M.	22, 32	Fujiwara H.	27	Hirakawa K.	44
Chen S.	50	Fujiwara T.	3	Hirano M.	17
Chen T.	104	Fukaura J.	63	Hirano T.	38, 52, 73, 74
Chiocca EA.	99	Fukuda K.	41	Hirayama F.	83
Clift S.	65	Fukumura M.	75	Hirose I.	8

Hirose M.	101, 108	Itoh A.	82	Kawasaki N.	23
Hiwasa T.	61	Itoh K.	68	Kay MA.	10, 11, 100
Honda K.	19	Itoh Y.	71	Kihara F.	83
Honma K.	94	Itokawa Y.	27	Kikuchi T.	26
Horiguchi K.	73, 74	Iwahashi M.	56	Kim JS.	111
Horiguchi T.	84	Iwasaki H.	34	Kim R.	45
Horikoshi N.	1	Iyama S.	63	King MA.	66
Hosaka M.	23	Izawa K.	32, 85	Kinoh H.	24
Hoshika A.	67, 102	Joo SY.	111	Kishida T.	27, 43, 79
Huang K.	106	Kadomatsu K.	39	Klein RL.	66
Iba H.	98	Kagawa S.	3	Kobayashi E.	67, 102
Ichikawa T.	47	Kagawa Y.	90	Kobayashi N.	50
Ideno J.	19	Kajita Y.	6	Kobune M.	20, 64
Igarashi T.	15	Kakizoe T.	65	Kohnno M.	76
Iida A.	24, 34, 95	Kamata Y.	16	Koike H.	88
Iimuro Y.	38, 52, 73, 74	Kambara H.	42, 47	Koizumi N.	96
Ikeda U.	78	Kanaji A.	16	Kojima H.	4
Ikeda Y.	92	Kanaya T.	95	Komaba S.	75
Ikeguchi K.	37	Kaneda Y.	59, 86	Komatsu N.	9
Ikejima M.	87	Kaneko S.	4, 58	Komori K.	36
Ikemoto T.	69	Kanemura H.	73, 74	Kosaka K.	44
Ikenaka K.	80	Kasahara N.	104, 105	Kosuga M.	16
Imamura T.	17	Katagiri T.	32	Kotin RM.	12
Imanishi J.	27, 43, 62, 79	Katane M.	81	Koya R.	105
Inaba T.	51	Kataoka M.	3	Kubo S.	13
Inoue A.	76	Katayama Y.	97	Kubo T.	86
Inoue M.	24, 75, 95	Kato H.	23	Kubo Y.	81
Ishibashi S.	19	Kato I.	89	Kujime Y.	101, 108
Ishibashi T.	92	Kato K.	15	Kume A.	9, 19, 21, 25
Ishii S.	20	Kato M.	15		37, 67, 78, 82, 97, 102
Ishizaki M.	15	Katsura K.	97	Kumon H.	7
Ito T.	98	Kawai K.	65	Kuramoto T.	50
Ito Y.	1, 20, 64	Kawamura K.	60	Kurozumi K.	42, 47

Kuwabara T.	22	Miki M.	77	Nagai M.	51
Kuwahara T.	34	Miki T.	62	Nagai Y.	95
Kuwayama Y.	53, 54, 55	Minowa S.	1	Nagamine T.	1
Levine AM.	105	Misumi M.	53, 54, 55	Nagasawa T.	4, 58
Li X.	22, 32, 85	Mitani K.	13, 28, 106	Nagashima T.	9, 21
Lieber A.	2	Mitsubishi J.	1	Nagatsu T.	37
Liu A.	49	Mitsunaga F.	17	Nagayama Y.	40
Logg A.	104	Miyagoe-Suzuki Y.	69, 71	Nakagawa K.	91
Logg C.	104	Miyake K.	5, 15, 31, 57	Nakai H.	10, 11, 100
Lu YY.	37	Miyazaki M.	92	Nakamori M.	56
Müller M.	107	Miyoshi H.	22, 32, 85	Nakamura A.	3
Maeda M.	72, 75	Mizuguchi H.	29, 40, 82, 96	Nakamura H.	23
Maeda Y.	78	Mizukami H.	19, 25, 33, 37	Nakamura K.	20
Maekawa T.	65		67, 78, 82, 97, 102	Nakamura M.	56
Maemondo M.	26	Mizuno M.	6, 62	Nakamura S.	17
Manabe A.	8	Mizutani T.	98	Nakamura T.	64, 77
Martins RW.	99	Mizutani Y.	62	Nakamura Y.	32
Masuda S.	69	Mochizuki H.	58	Nakane M.	1
Masuzawa T.	51	Mochizuki S.	67, 102	Nakanishi H.	62
Matsubara S.	39	Monma M.	65	Nakano I.	37
Matsubara Y.	67	Montini N.	10, 11	Nakao K.	40
Matsuda J.	72	Mori K.	93	Nakao M.	62
Matsui A.	4	Morikawa S.	52	Nakashima Y.	91
Matsukawa N.	80	Morimoto J.	84	Nakauchi H.	4, 58
Matsumoto K.	110	Morishita R.	59, 88	Nakazaki Y.	32, 65, 85
Matsushita T.	37, 97, 102	Moriuchi S.	53, 54, 55	Nakazawa S.	22
Matuura I.	56	Mulligan R.	65	Nanba E.	72
Mazda O.	27, 43, 62, 79	Muramatsu M.	53, 54, 55	Narita M.	49
Mcvey D.	93	Muramatsu S.	37, 102	Narumi K.	26
Meng XL.	70	Muramatsu T.	39	Nasu Y.	7
Metzger ME.	89	Murata T.	101, 108	Niitsu Y.	26, 63
Meuse L.	10, 11	Murawaki Y.	48	Nishina M.	98
Meyer EM.	66	Nagahara S.	94	Nishino T.	14

Nishioka C.	32	Ono Y.	42, 47	Sato T.	63
Nomoto T.	78, 97	Onodera M.	4, 25, 58	Sato Y.	63
Noro T.	57	Oshima K.	86	Satoh N.	65
Nose M.	76	Otomo T.	59	Seino Y.	18
Nukiwa T.	26, 77	Otsuka S.	47	Sellers S.	89
Ochiai T.	61	Otsuka Y.	80	Seo E.	41
Ochiya T.	94	Otsuki Y.	84	Shen JS.	70
Odaka M.	46	Oyaizu N.	65	Sherwin S.	65
Ogata A.	23	Ozawa K.	9, 19, 21, 25	Shibata H.	1, 9, 21
Ogawa Y.	72	33, 37, 51, 67, 78, 82, 97, 102		Shibata M.	84
Ogihara T.	88	Powell S.	100	Shimada H.	61
Ogusi I.	38	Pullarkat V.	105	Shimada K.	78
Ohara K.	15	Ramsey WJ.	25	Shimada T.	5, 15, 18, 31, 57, 87
Ohashi T.	70	Saeki Y.	59, 99	Shimazaki K.	97
Ohata J.	65	Sagawa T.	63	Shimizu T.	58
Ohgawara S.	78	Saijo Y.	26	Shimozato O.	60
Ohmoto T.	42, 47	Saika T.	7	Shimpo M.	78
Ohshima A.	72	Saiki M.	22, 32, 85	Shimuzu K.	17
Ohtsuka S.	42	Saisho H.	60	Shinoda S.	51
Oiwa M.	32	Saito T.	19	Shiota G.	48
Ojika K.	80	Saji H.	23	Shirakura M.	75, 95
Ojima T.	56	Sakakibara H.	30, 103	Shoji F.	91
Okada M.	17	Sakamaki T.	16	Shoji T.	36
Okada T.	25, 37, 51, 67	Sakamoto M.	69	Soda Y.	22, 32, 85
	78, 82, 97, 102	Sakamoto T.	92	Son G.	38
Okano J.	48	Sakiyama S.	39, 60	Stamatoyannopoulos G.	14
Okano S.	91	Sakuraba H.	18	Storm TA.	10, 11, 100
Oku T.	63	Sakurai F.	29	Stripecke R.	105
Okuda K.	33	Sano A.	94	Sueishi K.	34, 36, 91, 92
Okuda T.	19	Sasaki E.	32, 85	Sugimachi K.	36, 91
Okumura K.	65	Sasaki K.	20, 64	Sugimoto Y.	1
Okuyama T.	16	Sasaki M.	76	Sugita K.	22
Ono F.	34	Sato A.	90	Sumazaki R.	4

Sumiyoshi T.	63	Tani Y.	110	Utoguchi N.	96
Suzuki E.	101, 108	Taniyama Y.	88	Wada K.	83
Suzuki N.	5, 15, 31, 57	Tazawa R.	26	Wada T.	20
Suzuki T.	53, 54, 55	Terada K.	99	Wakabayashi T.	6
Suzuki Y.	72	Terada M.	94	Wakimoto H.	99
Tabata T.	92	Terao K.	9, 21, 34	Wakumoto Y.	65
Tagawa M.	39, 60	Thomas CE.	100	Wang LJ.	37
Tahara M.	77	Thompson TC.	7	Wang W.	104
Tai CK.	104	Toba K.	49	Wang Y.	60
Taira K.	22	Tobimatsu S.	92	Warashina M.	22
Takahashi H.	15, 18	Toge T.	45	Washizawa K.	24, 75
Takahashi K.	32, 65	Tojo A.	22, 32, 65, 85	Watabe K.	75
Takahashi M.	26, 49, 63	Tokusumi Y.	95	Watanabe A.	98
Takahashi S.	1	Tomikawa S.	65	Watanabe M.	77
Takahashi T.	32	Tomita N.	88	Watanabe S.	101, 108
Takakura Y.	50	Tomizawa M.	39	Watanabe Y.	50, 96
Takao E.	81	Toyama Y.	16	Watari K.	65
Takata I.	22	Tsuda H.	20	Wei L.	93
Takatoku M.	21, 89	Tsuji K.	8	Wright F.	100
Takaura N.	72	Tsukahara S.	1	Xin KQ.	33
Takeda S.	69, 71	Tsuruo T.	1	Yagi T.	72
Takeuchi K.	51, 78	Tsushima T.	7	Yamada M.	16
Takeuchi M.	73, 74	Tyminski E.	99	Yamada Y.	63
Takeuchi T.	79	Uchida E.	57	Yamagishi H.	27
Tamiya T.	42, 47	Uchida H.	20, 64	Yamaguchi T.	51, 60
Tanabe A.	16	Ueda K.	56	Yamamichi N.	98
Tanabe K.	45	Ueda R.	80	Yamamoto S.	59
Tanabe T.	22	Ueda Y.	9, 21, 27, 30, 92, 103	Yamamoto T.	24, 75
Tanaka A.	72	Uekama K.	83	Yamano T.	72
Tanaka H.	44	Ueki T.	52, 73, 74	Yamashita N.	8, 65
Tanaka N.	3, 41	Ugai H.	41, 101, 108	Yamaue H.	56
Tanaka T.	46	Ugai S.	60	Yamazaki Y.	46, 57
Tani K.	22, 32, 65, 85	Urabe M.	12	Yannaki E.	14

Yashiro M.	44	Yonemitsu Y.	34, 36, 91, 92	Yoshino I.	91
Yasui K.	110	Yoshida J.	6, 62	Yoshioka T.	78
Yasutomi K.	79	Yoshida K.	53, 54, 55	Yu L.	39
Yokota T.	69	Yoshikawa Y.	75	Yuasa H.	80
Yokoyama K.	41, 101, 108	Yoshimura M.	69	Yuasa K.	69